rEVO Biologics, Inc. is led by a team of business experts and scientists with a successful track record of developing and commercializing important and highly innovative healthcare technologies and life-changing therapeutics.
 

Yann Echelard, Ph.D.

President and CEO

Read More

Yann Echelard, Ph.D.

President and CEO

Yann Echelard has served as rEVO’s chief executive officer and a member of the board of directors since May 2012 and has held various positions with the Company since January 1994 when it was known as Genzyme Transgenics Corporation, including vice president of research and development and vice president of corporate and technology development. Dr. Echelard spearheaded the creation of a collaborative joint venture with LFB Biotech in 2006. This close collaboration led to the acquisition of the company by LFB Biotech in December 2010. Dr. Echelard currently serves as a director of TG Therapeutics (NASDAQ: TGTX) and as a director of GTC Biotherapeutics UK Limited, a subsidiary of LFB USA.

Dr. Echelard holds a Ph.D. in Microbiology and Immunology from the Université de Montréal and has completed post-doctoral studies at the Ludwig Institute of Cancer Research (at McGill University), the Roche Institute (Nutley, NJ) and Harvard University.

Rick Finnegan

Rick Finnegan

Senior Vice President, Program Management

Read More

Rick Finnegan

Senior Vice President, Program Management

Rick Finnegan returned to rEVO in 2014 as senior vice president of program management previously serving as vice president of corporate development for the company from 2007 to 2008 when it known as Genzyme Transgenics Corporation. Prior to rEVO, Mr. Finnegan was executive vice president for global strategic accounts and commercial development at inVentiv Health from 2010 to 2013 where he expanded inVentiv's commercial footprint into China and Europe.  From 1984 through 2010, Mr. Finnegan's experience included roles at leading biopharma companies including twelve years in various commercialization assignments at Merck, two years at Genzyme as vice president of new products, three years as senior vice president of sales and marketing at Critical Therapeutics, and three years at Glenmark Pharmaceuticals where, based in Prague, he led their European specialty pharma business.

 

Mr. Finnegan holds a B.S. in business administration with a concentration in life sciences from the Whittemore School of Business and Economics at the University of New Hampshire and an M.S. in management from the Sloan School of Management at Massachusetts Institute of Technology.

Robert Greif

Senior Vice President of Commercial Operations

Read More

Robert Greif

Senior Vice President of Commercial Operations

Robert Greif has served as rEVO’s senior vice president commercial operations since May 2011. Mr. Greif joined rEVO from UnitedHealth Group where he served as senior vice president, global business development since 2008. Prior to 2008, he was Vice President of Managed Markets at Boehringer Ingelheim.  During his five year tenure at BI, he held various leadership roles with increasing levels of responsibilities in sales, marketing and managed markets focusing on the cardiovascular, respiratory and neurology marketplaces. Prior to joining Boehringer Ingelheim, Mr. Greif held a variety of commercial roles at Sanofi where he launched many blockbuster products.

Mr. Greif holds a B.S. in public relations from Western Kentucky University and an M.B.A. in management from the Lubin School of Business at Pace University.

Brad Simas

Controller

Read More

Brad Simas

Controller

Brad Simas joined rEVO as Assistant Controller in March 2013 and now holds the position of Controller. He brings over 10 years of experience in corporate finance and accounting. Previous to rEVO, Mr. Simas worked as Assistant Controller for Network Engines, Inc. (now Unicom Engineering, Inc.), a high tech manufacturing company. Prior to that, he spent 6 years in public accounting at Deloitte & Touche LLP, where he led financial statement and internal control audits of private and publicly traded companies.

Mr. Simas holds a Bachelor of Science degree from Bentley University, a Masters of Accounting degree from the McCallum Graduate School at Bentley and is licensed as a certified public accountant.